Emerging Markets

Latest Headlines

Latest Headlines

GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts

New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.

JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets

Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese companies see the tie-ups as a way to build their own capabilities and begin to tap lucrative Western markets.

India sets controversial price caps on 650 drugs

India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.

GSK tries novel approach in emerging markets: price cuts

GlaxoSmithKline CFO Simon Dingemans has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.

PPD's BioDuro opens Shanghai discovery lab

BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.

Taliban drops campaign against polio vaccine

When scientists set a 2018 target for eradicating polio last month, fresh memories of the violence against vaccinators offset the optimism. Short, low-profile campaigns--almost guerilla-like--were proposed as the safest way to vaccinate. Now the situation in Afghanistan might be improving.

Pfizer to pick some contract manufacturers for new elevated role

Pfizer's "external partner management" process is not exactly "American Idol" and Pfizer's John F. Kelly is not exactly Simon Cowell, but this year the Pfizer Global Supply (PGS) unit will go through the exercise of turning a handful or two of its more than 200 contractors into stars.

Indian rotavirus vax set to undercut GSK and Merck

Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.

WuXi's revenue jumps 11.7% in strong Q1

WuXi PharmaTech, China's largest CRO, has big expectations for 2013, and the company is well on its way to following through, posting an 11.7% revenue jump in the first quarter.

Astellas chops OSI, Perseid ops in global R&D restructuring

Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort, shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics subsidiaries and cutting back its work at the Astellas Research Institute of America to focus solely on CNS diseases.